In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Identifying and optimizing the Medical Affairs talent pool
Insights from the MAPS New Orleans 2025 roundtable session. The session highlighted the essential talent needs—such as competencies, qualifications, and...